MedPath

Multiinstitutional study on evaluation methods of renal function before and during chemotherapy for urothelial cancer

Not Applicable
Conditions
nresectable or metastatic urothelial carcinoma treated with systemic chemotherapy
Registration Number
JPRN-UMIN000007601
Lead Sponsor
Department of Urology, Tsukuba University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
370
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients given the first systemic chemotherapy before December 31, 2003. 2. Patients with active cancers in other organs at the start of systemic chemotherapy.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The rate of dose modification in the 1st-line chemotherapy.
Secondary Outcome Measures
NameTimeMethod
1. The rate of regimen modification in the 1st-line chemotherapy. 2. Response rate in the 1st-line chemotherapy. 3. Overall survival rate. 4. Cancer-specific survival rate 5. Frequency of adverse effects. 6. Response rate in the 2nd-line chemotherapy. 7. Response rate in the 3rd-line chemotherapy. 8. Correlation among the measured results in renal function by different methods.
© Copyright 2025. All Rights Reserved by MedPath